The SVP, Bus Dev & Corp Planning of Trevena Inc (NASDAQ: TRVN) is Buying SharesBy Carrie Williams
Following this transaction Yacoub Habib’s holding in the company was increased by 100%. In addition to Yacoub Habib, one other TRVN executive reported Buy trades in the last month.
The company has a one year high of $13.02 and a one year low of $3.76. Currently, Trevena Inc has an average volume of 705.3K.
Based on 5 analyst ratings, the analyst consensus is Strong Buy with an average price target of $12.90, reflecting a -65.0% downside. Starting in February 2014, TRVN received 63 Buy ratings in a row. 10 different firms, including Brean Capital and Cowen & Co., currently also have a Buy rating on the stock.
Trevena, Inc. is a clinical stage biopharmaceutical company, which discovers, develops and intends to commercialize therapeutics that use a novel approach to target G protein coupled receptors. Its product pipeline consists of TRV027, which is an intravenous drug for the treatment of acute heart failure in combination with standard diuretic therapy; TRV130, which is an intravenous G protein biased ligand that targets the mu opioid receptor; TRV734, which is a follow-on program to the TRV130 mu opioid biased ligand program, and is expected to have pharmacokinetics amenable to chronic oral administration; and Delta Opiod. The company was founded by Robert Joseph Lefkowitz, Scott DeWire, Howard A. Rockman, Jonathan Violin and Erin Whalen on November 9, 2007 and is headquartered in King of Prussia, PA.